These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30108834)

  • 1. Pyrazolo[3,4-
    Díaz JL; Corbera J; Cuberes R; Contijoch M; Enrech R; Yeste S; Montero A; Dordal A; Monroy X; Almansa C
    Medchemcomm; 2017 Jun; 8(6):1235-1245. PubMed ID: 30108834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazolo[3,4-
    Díaz JL; Corbera J; Martínez D; Bordas M; Sicre C; Pascual R; Pretel MJ; Marín AP; Montero A; Dordal A; Alvarez I; Almansa C
    Medchemcomm; 2017 Jun; 8(6):1246-1254. PubMed ID: 30108835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the Selectivity Profile of Sigma Receptor Ligands by Molecular Docking and Pharmacophore Analyses.
    Righetti G; Tonelli M; Fossa P; Cichero E
    Med Chem; 2021; 17(10):1151-1165. PubMed ID: 33155928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship study of a new series of selective σ(1) receptor ligands for the treatment of pain: 4-aminotriazoles.
    Díaz JL; Christmann U; Fernández A; Torrens A; Port A; Pascual R; Álvarez I; Burgueño J; Monroy X; Montero A; Balada A; Vela JM; Almansa C
    J Med Chem; 2015 Mar; 58(5):2441-51. PubMed ID: 25658964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and SAR of 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines as potent serotonin 5-HT6 receptor antagonists.
    Ivachtchenko AV; Golovina ES; Kadieva MG; Kysil VM; Mitkin OD; Tkachenko SE; Okun I
    Bioorg Med Chem; 2011 Feb; 19(4):1482-91. PubMed ID: 21277782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting σ
    Wood MD; Sahn JJ; Martin SF
    Eur J Med Chem; 2022 Dec; 243():114696. PubMed ID: 36088757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigating isoindoline, tetrahydroisoquinoline, and tetrahydrobenzazepine scaffolds for their sigma receptor binding properties.
    Linkens K; Schmidt HR; Sahn JJ; Kruse AC; Martin SF
    Eur J Med Chem; 2018 May; 151():557-567. PubMed ID: 29656199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Affinity relationships of novel σ
    Walby GD; Gu Q; Yang H; Martin SF
    Bioorg Chem; 2024 Apr; 145():107191. PubMed ID: 38432153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of novel 6,7-dihydro-5H-cyclopenta[d]pyrimidine and 5,6,7,8-tetrahydroquinazoline derivatives as sigma-1 (σ1) receptor antagonists for the treatment of pain.
    Lan Y; Songyang Y; Zhang L; Peng Y; Song J
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2051-6. PubMed ID: 26947609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of novel sigma-1 receptor antagonists based on pyrimidine scaffold as agents for treating neuropathic pain.
    Lan Y; Chen Y; Cao X; Zhang J; Wang J; Xu X; Qiu Y; Zhang T; Liu X; Liu BF; Zhang G
    J Med Chem; 2014 Dec; 57(24):10404-23. PubMed ID: 25420090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor.
    Squarcialupi L; Catarzi D; Varano F; Betti M; Falsini M; Vincenzi F; Ravani A; Ciancetta A; Varani K; Moro S; Colotta V
    Eur J Med Chem; 2016 Jan; 108():117-133. PubMed ID: 26638043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 7 H-Pyrrolo[2,3- d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1 H-Pyrazolo[3,4- d]pyrimidin-4-amine-Based Inhibitors.
    Vidadala RSR; Golkowski M; Hulverson MA; Choi R; McCloskey MC; Whitman GR; Huang W; Arnold SLM; Barrett LK; Fan E; Merritt EA; Van Voorhis WC; Ojo KK; Maly DJ
    ACS Infect Dis; 2018 Apr; 4(4):516-522. PubMed ID: 29522315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Sigma-2 Receptor-Specific Binding Sites Using [
    Weng CC; Riad A; Lieberman BP; Xu K; Peng X; Mikitsh JL; Mach RH
    Pharmaceuticals (Basel); 2022 Dec; 15(12):. PubMed ID: 36559015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of some novel pyrazolopyrimidines incorporating a benzothiazole ring system.
    Azam MA; Dharanya L; Mehta CC; Sachdeva S
    Acta Pharm; 2013 Mar; 63(1):19-30. PubMed ID: 23482310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of a new series of hexahydro-2H-pyrano[3,2-c]quinolines as novel selective σ1 receptor ligands.
    Díaz JL; Christmann U; Fernández A; Luengo M; Bordas M; Enrech R; Carro M; Pascual R; Burgueño J; Merlos M; Benet-Buchholz J; Cerón-Bertran J; Ramírez J; Reinoso RF; Fernández de Henestrosa AR; Vela JM; Almansa C
    J Med Chem; 2013 May; 56(9):3656-65. PubMed ID: 23560650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation of novel analogs of 2-arylpiperidines and evaluation of their sigma receptor binding affinities.
    Walby GD; Martin SF
    Eur J Med Chem; 2022 May; 235():114310. PubMed ID: 35395511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation.
    Squarcialupi L; Colotta V; Catarzi D; Varano F; Filacchioni G; Varani K; Corciulo C; Vincenzi F; Borea PA; Ghelardini C; Di Cesare Mannelli L; Ciancetta A; Moro S
    J Med Chem; 2013 Mar; 56(6):2256-69. PubMed ID: 23427825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, anticancer and radioprotective activities of some new pyrazolo[3,4-d]pyrimidines containing amino acid moieties.
    Ghorab MM; Ragab FA; Noaman E; Heiba HI; Aboulmagd SA
    Arzneimittelforschung; 2009; 59(2):96-103. PubMed ID: 19338140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.